FDA Advisory Panel Undecided On Fablyn’s Mortality Trend
This article was originally published in The Pink Sheet Daily
Executive Summary
Reproductive Health Drugs advisory panel concludes the benefits of Pfizer’s lasofoxifene outweigh its risks in specific populations of women with postmenopausal osteoporosis.